We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon's Rare Disease Drug Quinsair Launched in Canada
Read MoreHide Full Article
Horizon Pharma plc announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections caused by Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). Notably, Quinsair is the first inhaled fluoroquinolone antibiotic to gain marketing authorization from Health Canada and has also approved in the EU for the same indication.
Horizon’s share price has fallen 19.6% in the past one month, underperforming the Zacks classified Medical-Biomedical and Genetics industry’s decline of 2.3%.
According to the company’s press release, CF is a rare, life threatening disease that affects about 75,000 people across the world and over 4,100 people in Canada. Moreover, Pseudomonas aeruginosa, is one of the most common bacteria which causes lung infections in people living with CF. Consequently, chronic management is deemed necessary on detection of the bacteria in a patient.
Notably, Quinsair became a part of Horizon’s portfolio following the acquisition of Raptor Pharmaceutical Corp. in Oct 2016.
In a separate press release, Horizon announced that the U.S. Patent and Trademark Office (USPTO) has issued an additional Notice of Allowance for U.S. patent application number 13/610,580 with claims covering Ravicti (glycerol phenylbutyrate) oral liquid.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to be issued under this application will expire on Sep 22, 2030. After the issuance, Horizon plans to list it in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. This will be the seventh U.S. patent to be listed in the Orange Book for Ravicti.
Ravicti is approved in the U.S. and the EU for use as a nitrogen-binding agent for chronic management of adult and pediatric patients greater than two years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation.
Ravicti became a part of Horizon’s portfolio as a result of the Hyperion Therapeutics acquisition in May 2015.
Zacks Rank & Key Picks
Horizon currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 86.6% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 15% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 9.2% and 3.5%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 29.8% year to date.
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Horizon's Rare Disease Drug Quinsair Launched in Canada
Horizon Pharma plc announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections caused by Pseudomonas aeruginosa in adult patients with cystic fibrosis (CF). Notably, Quinsair is the first inhaled fluoroquinolone antibiotic to gain marketing authorization from Health Canada and has also approved in the EU for the same indication.
Horizon’s share price has fallen 19.6% in the past one month, underperforming the Zacks classified Medical-Biomedical and Genetics industry’s decline of 2.3%.
According to the company’s press release, CF is a rare, life threatening disease that affects about 75,000 people across the world and over 4,100 people in Canada. Moreover, Pseudomonas aeruginosa, is one of the most common bacteria which causes lung infections in people living with CF. Consequently, chronic management is deemed necessary on detection of the bacteria in a patient.
Notably, Quinsair became a part of Horizon’s portfolio following the acquisition of Raptor Pharmaceutical Corp. in Oct 2016.
In a separate press release, Horizon announced that the U.S. Patent and Trademark Office (USPTO) has issued an additional Notice of Allowance for U.S. patent application number 13/610,580 with claims covering Ravicti (glycerol phenylbutyrate) oral liquid.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The patent scheduled to be issued under this application will expire on Sep 22, 2030. After the issuance, Horizon plans to list it in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. This will be the seventh U.S. patent to be listed in the Orange Book for Ravicti.
Ravicti is approved in the U.S. and the EU for use as a nitrogen-binding agent for chronic management of adult and pediatric patients greater than two years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation.
Ravicti became a part of Horizon’s portfolio as a result of the Hyperion Therapeutics acquisition in May 2015.
Zacks Rank & Key Picks
Horizon currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care sector include Cambrex Corporation , Heska Corporation and Anika Therapeutics Inc. (ANIK - Free Report) . While Cambrex and Heska sport a Zacks Rank #1 (Strong Buy), Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates improved 19.5% for 2016 and 10.9% for 2017 in the last 60 days. The company posted a positive earnings surprise in each of the four trailing quarters, with an average beat of 301.64%. Its share price has increased 86.6% year to date.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 15% year to date.
Anika’s earnings estimates for 2016 and 2017 were up 9.2% and 3.5%, respectively in the last 60 days. The company has recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price is up 29.8% year to date.
HORIZON PHARMA Price
HORIZON PHARMA Price | HORIZON PHARMA Quote
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017? Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>